1921
Volume 76, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Severe thrombocytopenia and increased vascular permeability are two major characteristics of dengue hemorrhagic fever (DHF). An immune mechanism of thrombocytopenia due to increased platelet destruction appears to be operative in patients with DHF (see Saito et al., 2004, 138: 299–303; Mitrakul, 1979, 26: 975–984; and Boonpucknavig, 1979, 28: 881–884). The interim data of two randomized placebo controlled trials in patients ( = 47) meeting WHO criteria for dengue hemorrhagic fever (DHF) with severe thrombocytopenia (platelets ≤ 50,000/mm) reveal that the increase in platelet count with anti-D immune globulin (WinRho® SDF), 50 μg/kg (250 IU/kg) intravenously is more brisk than the placebo group. The mean maximum platelet count of the anti-D–treated group at 48 hours was 91,500/mm compared with 69,333/mm in the placebo group. 75% of the anti-D–treated group demonstrated an increase of platelet counts ≥ 20,000 compared with only 58% in the placebo group. These data suggest that treatment of severe thrombocytopenia accompanying DHF with anti-D may be a useful and safe therapeutic option.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.76.737
2007-04-01
2017-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/4/0760737.html?itemId=/content/journals/10.4269/ajtmh.2007.76.737&mimeType=html&fmt=ahah

References

  1. Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, Robles AM, Estrella BD Jr, Kumatori A, Moji K, Alonzo MT, Buerano CC, Matias RR, Morita K, Natividad FF, Nagatake T, 2004. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol 138 : 299–303.
  2. Mitrakul C, 1979. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 26 : 975–984.
  3. Boonpucknavig S, 1979. Demonstration of dengue antibody complexes on the surface of platelets from patients with dengue hemorrhagic fever. Am J Trop Med Hyg 28 : 881–884.
  4. Gubler DJ, Clark GG, 1996. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1(2). Available at: http://www.cdc.gov/ncidod/eid/vol1no2/gubler.htm.
  5. McMillan R, 1981. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 304 : 1135–1147.
  6. Cines DB, 2002. Immune thrombocytopenic purpura. N Engl J Med 346 : 995–1008.
  7. Muller-Eckhardt C, 1980. The clinical significance of platelet-associated IgG: a study on 298 patients with various disorders. Br J Haematol 46 : 123–131.
  8. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV, 1998. Dengue and dengue hemorrhagic fever [seminar]. Lancet 352 : 971–977.
  9. Nimmannitya S, 1999. Dengue hemorrhagic fever: disorders of hemostasis. IX Congress of the International Society of Haematology Asia-Pacific Division, Bangkok, October 24–28, 1999, pp 184–187. Available at: http://www.ishapd.org/1999/50.pdf
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.737
Loading
/content/journals/10.4269/ajtmh.2007.76.737
Loading

Data & Media loading...

  • Received : 01 Sep 2006
  • Accepted : 09 Dec 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error